Trial results

A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight

NCT05726227 on ClinicalTrials.gov · last registry update 2026-08-07

A small phase 3 — 210 participants, against a typical 424. The sponsor logged completion for 15 October 2025. Primary outcome, as filed: Group Kids: Change in body mass index (BMI). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

210

Started

2023-07-07

Primary completion

2025-10-15 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Group Kids: Change in body mass index (BMI)

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.